Buscar
Amarin Corporation PLC
AMRNAñadir a la lista de seguimiento
14.260USD
+0.030+0.21%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
301.21MCap. mercado
PérdidaP/E TTM
Más Datos de Amarin Corporation PLC Compañía
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Información de Amarin Corporation PLC
Símbolo de cotizaciónAMRN
Nombre de la empresaAmarin Corporation PLC
Fecha de salida a bolsaApr 01, 1993
Director ejecutivoBerg (Aaron D)
Número de empleados275
Tipo de seguridadDepository Receipt
Fin del año fiscalApr 01
DirecciónWeWork One Central Plaza Dame Street
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD02 K7K5
Teléfono35316699020
Sitio Webhttps://amarincorp.com/
Símbolo de cotizaciónAMRN
Fecha de salida a bolsaApr 01, 1993
Director ejecutivoBerg (Aaron D)
Ejecutivos de Amarin Corporation PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
235.92K
+0.75%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
8.42K
+4.75%
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Keith L. Horn
Mr. Keith L. Horn
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
235.92K
+0.75%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
8.42K
+4.75%
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Amarin Corporation PLC?
Los cinco principales accionistas de Amarin Corporation PLC son: Dr. David Keenan, Ph.D.
¿Cuántas instituciones poseen acciones de Amarin Corporation PLC (AMRN)?
A fecha de 2026Q1, 280 instituciones poseen acciones de Amarin Corporation PLC, con un valor de mercado combinado de aproximadamente 4.71M, lo que representa el 22.72% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -402415.00.